Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Bionomics, an Australian small-molecule drug discovery firm, has licensed to Merck & Co. its BNC375 research program targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system disorders. Merck will fund all R&D and will commercialize any resulting products. Bionomics will receive $20 million up front and is eligible for up to $506 million in milestone payments. The two companies signed a similar agreement last year around pain treatments.
This article has been sent to the following recipient: